Investor-ready strategy: Integrated evidence planning to maximize commercial opportunity

Securing investment or acquisition in today’s highly competitive funding environment requires more than presenting a promising product. Biotech companies must also offer a value story that demonstrates a clinical and commercial path to market. The most compelling value story starts with an integrated evidence generation plan (IEGP), a comprehensive strategy for meeting the evidentiary needs of all stakeholders.

Among those stakeholders? Potential funders — and a robust IEGP is the surest way to earn their confidence. An IEGP gives you an advantage with investors by equipping you to:

• Investigate multiple indications through creative, flexible trial design
• Validate the commercial value of all feasible indications
• Address complex regulatory requirements and pursue pathways to early approval by tapping into internal and external regulatory expertise
• Prioritize early patient awareness and engagement for faster market uptake — particularly important for treatments for rare diseases
• Develop realistic market estimates and pricing strategies that will contribute to profitability and confirm the credibility of investment opportunities

When assessing your asset’s commercial potential, prospective funders and buyers will scrutinize each decision your team has made along the way. An IEGP justifies your development path, showing that it’s underpinned by data and thoughtful strategy. It also highlights your understanding of the unmet need your product targets and assures investors that you have science-backed approaches for verifying the therapeutic impact of a product and its likely success in the market.

In our experience, an IEGP is the most efficient, cost-effective way to build funder confidence. The resulting value story demonstrates not only regulatory acceptability but that providers will prescribe your product, patients will trust it, and payers and health care systems will reimburse for its use. 

To learn more about how IEGPs can lead to greater commercial success, join Parexel Biotech for an on-demand webinar. We’ll discuss:

• Addressing common evidence gaps, including insufficient study size and lack of biomarker strategy
• Balancing the need for both speed and comprehensive data generation. This begins with cross-functional consensus on milestone-specific objectives and the types of evidence necessary for achieving them
• Using diverse data sources, including real-world data, to create compelling investor narratives and make a value-based case for your product
• Communicating effectively with multiple stakeholders, including investors

In under an hour, our experts will illustrate how IEGPs help you defend strategy decisions, differentiate your product, and deliver a robust evidence package that goes beyond clinical data. We’ll also discuss models for partnership and how our team can help yours design and execute a strategy that gives your product an edge.

When raising capital, an evidence plan significantly strengthens your position — and the earlier you develop it, the sooner you benefit. Our experts can help you begin. 
 

Watch now

Return to Insights Center